Valproate Adjuvant Cognitive Behavioral Therapy in Panic Disorder Patients With Comorbid Bipolar Disorder: Case Series and Review of the Literature

다국어 초록 (Multilingual Abstract)

Anxiety disorders are the most common comorbid psychiatric disorders in patients with bipolar disorder. Managing anxiety symptoms in comorbid conditions is challenging and has received little research interest. The findings from preclinical research on fear conditioning, an animal model of anxiety disorder, have suggested that memory recon solidation updating (exposure-based therapy) combined with valproate might facilitate the amelioration of fear memories. Here, three cases of successful amelioration of agoraphobia and panic symptoms through valproate adjuvant therapy for cognitive behavioral therapy in patients who failed to respond to two to three consecutive standard pharmacotherapy trials over several years are described. To the best of the author’s knowledge, this is the first attempt to combine CBT with valproate in patients with panic disorder, agoraphobia, and comorbid bipolar disorder. Additionally, the background preclinical research on this combination therapy based on the reconsolidation-updating mechanism, the inhibition of histone deacetylase 2, and critical period reopening, off-label use of valproate in panic disorder, plasticity-augmented psychotherapy, and how to combine valproate with CBT is discussed.

참고문헌 (Reference)

1 강한철, "임상시험과 환자를 위한 구체적 의료행위의 구분기준에 관한 고찰 ‐ 대법원 2010. 10. 14. 선고 2007다3162 판결에 대한 비판적 검토를 중심으로 ‐" 법학연구소 54 (54): 185-217, 2013

2 이인향 ; 서미경 ; 이영숙 ; 계승희 ; 김현아 ; 이숙향, "의약품 허가외사용 관리 체계 발전 방안" 대한약학회 58 (58): 112-124, 2014

3 Goldberg JF, "Wrestling with antidepressant use in bipolar disorder: the ongoing debate" 82 : 19ac13181-, 2021

4 Kinrys G, "Valproic acid for the treatment of social anxiety disorder" 18 : 169-172, 2003

5 Göttlicher M, "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells" 20 : 6969-6978, 2001

6 Primeau F, "Valproic acid and panic disorder" 35 : 248-250, 1990

7 Atmaca A, "Valproic acid (VPA) in patients with refractory advanced cancer:a dose escalating phase I clinical trial" 97 : 177-182, 2007

8 Keck PE Jr, "Valproate treatment of panic disorder and lactate-induced panic attacks" 33 : 542-546, 1993

9 Gervain J, "Valproate reopens critical-period learning of absolute pitch" 7 : 102-, 2013

10 Winterer G, "Valproate and GABAergic system effects" 28 : 2050-2051, 2003

11 Aliyev NA, "Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study" 23 : 109-114, 2008

12 Careaga MBL, "Understanding posttraumatic stress disorder through fear conditioning, extinction and reconsolidation" 71 : 48-57, 2016

13 Ott CA, "Treatment of anxiety disorders in patients with comorbid bipolar disorder" 8 : 256-263, 2018

14 Kim JE, "The role of the amygdala in the pathophysiology of panic disorder : evidence from neuroimaging studies" 2 : 20-, 2012

15 Alberini CM, "The role of reconsolidation and the dynamic process of long-term memory formation and storage" 5 : 12-, 2011

16 Alberini CM, "The regulation of transcription in memory consolidation" 7 : a021741-, 2014

17 Goddard AW, "The neurobiology of panic: a chronic stress disorder" 1 : 2470547017736038-, 2017

18 Bredy TW, "The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear" 15 : 39-45, 2008

19 Maya Vetencourt JF, "The antidepressant fluoxetine restores plasticity in the adult visual cortex" 320 : 385-388, 2008

20 Schaffer A, "The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders" 24 : 6-22, 2012

21 Rodriguez-Romaguera J, "Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction" 65 : 887-892, 2009

22 Hibar DP, "Subcortical volumetric abnormalities in bipolar disorder" 21 : 1710-1716, 2016

23 Grieco SF, "Subanesthetic ketamine reactivates adult cortical plasticity to restore vision from amblyopia" 30 : 3591-3603.e8, 2020

24 Andrews G, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder" 52 : 1109-1172, 2018

25 Dresler T, "Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder" 120 : 3-29, 2012

26 Killick-Cole CL, "Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma" 12 : e0176855-, 2017

27 Heinrichs SC, "Repeated valproate treatment facilitates fear extinction under specific stimulus conditions" 552 : 108-113, 2013

28 Nabel EM, "Regulating critical period plasticity: insight from the visual system to fear circuitry for therapeutic interventions" 4 : 146-, 2013

29 Altshuler L, "Regional brain changes in bipolar I depression : a functional magnetic resonance imaging study" 10 : 708-717, 2008

30 Brunet A, "Reduction of PTSD symptoms with pre-reactivation propranolol therapy : a randomized controlled trial" 175 : 427-433, 2018

31 Bondarev AD, "Recent developments of HDAC inhibitors: emerging indications and novel molecules" 87 : 4577-4597, 2021

32 ReiffCM, "Psychedelics and psychedelic-assisted psychotherapy" 19 : 95-115, 2021

33 de Vos CMH, "Psychedelics and neuroplasticity:a systematic review unraveling the biological underpinnings of psychedelics" 12 : 724606-, 2021

34 de la Fuente Revenga M, "Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice" 37 : 109836-, 2021

35 Asthana MK, "Preventing the return of fear using reconsolidation update mechanisms depends on the Met-allele of the brain derived neurotrophic factor Val66Met polymorphism" 19 : pyv137-, 2016

36 Schiller D, "Preventing the return of fear in humans using reconsolidation update mechanisms" 463 : 49-53, 2010

37 Preti A, "Prevalence and treatment of panic disorder in bipolar disorder: systematic review and meta-analysis" 21 : 53-60, 2018

38 Yapici Eser H, "Prevalence and associated features of anxiety disorder comorbidity in bipolar disorder: a meta-analysis and meta-regression study" 9 : 229-, 2018

39 Niitsu T, "Predictors of switch from depression to mania in bipolar disorder" 66-67 : 45-53, 2015

40 Choi KY, "Plasticity-augmented psychotherapy for refractory depressive and anxiety disorders" 70 : 134-147, 2016

41 Gogolla N, "Perineuronal nets protect fear memories from erasure" 325 : 1258-1261, 2009

42 Maren S, "Parsing reward and aversion in the amygdala" 90 : 209-211, 2016

43 Woodman CL, "Panic disorder: treatment with valproate" 55 : 134-136, 1994

44 Simon NM, "Panic disorder and bipolar disorder: anxiety sensitivity as a potential mediator of panic during manic states" 87 : 101-105, 2005

45 Westra HA, "Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia" 16 : 233-246, 2002

46 Myers KM, "Mechanisms of fear extinction" 12 : 120-150, 2006

47 Mitchell JM, "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study" 27 : 1025-1033, 2021

48 Reinstatler L, "Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature" 15 : 37-43, 2015

49 van Apeldoorn FJ, "Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia" 117 : 260-270, 2008

50 Pappens M, "Interoceptive fear learning to mild breathlessness as a laboratory model for unexpected panic attacks" 6 : 1150-, 2015

51 Acheson DT, "Interoceptive fear conditioning as a learning model of panic disorder: an experimental evaluation using 20% CO(2)-enriched air in a non-clinical sample" 45 : 2280-2294, 2007

52 Gao K, "Independent predictors for lifetime and recent substance use disorders in patients with rapid-cycling bipolar disorder: focus on anxiety disorders" 19 : 440-449, 2010

53 Guan JS, "HDAC2 negatively regulates memory formation and synaptic plasticity" 459 : 55-60, 2009

54 Nott A, "HDAC2 expression in parvalbumin interneurons regulates synaptic plasticity in the mouse visual cortex" 1 : 34-40, 2015

55 Wakizono T, "Growth factors with valproic acid restore injury-impaired hearing by promoting neuronal regeneration" 6 : e139171-, 2021

56 de Quervain D, "Glucocorticoid-induced enhancement of extinction-from animal models to clinical trials" 236 : 183-199, 2019

57 NICE, "Generalised anxiety disorder and panic disorder in adults: management (CG113)"

58 Karpova NN, "Fear erasure in mice requires synergy between antidepressant drugs and extinction training" 334 : 1731-1734, 2011

59 Monfils MH, "Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories" 324 : 951-955, 2009

60 Costanzi M, "Extinction after retrieval: effects on the associative and nonassociative components of remote contextual fear memory" 18 : 508-518, 2011

61 Silingardi D, "Epigenetic treatments of adult rats promote recovery from visual acuity deficits induced by long-term monocular deprivation" 31 : 2185-2192, 2010

62 GräffJ, "Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories" 156 : 261-276, 2014

63 Eden AS, "Emotion regulation and trait anxiety are predicted by the microstructure of fibers between amygdala and prefrontal cortex" 35 : 6020-6027, 2015

64 Baetz M, "Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy" 43 : 73-77, 1998

65 de Angelis L, "Effects of valproate and lorazepam on experimental anxiety:tolerance, withdrawal, and role of clonidine" 52 : 329-333, 1995

66 Davis AK, "Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial" 78 : 481-489, 2021

67 Bach DR, "Effect of valproate and pregabalin on human anxiety-like behaviour in a randomised controlled trial" 8 : 157-, 2018

68 Päären A, "Early risk factors for adult bipolar disorder in adolescents with mood disorders: a 15-year follow-up of a community sample" 14 : 363-, 2014

69 Du N, "Do some anxiety disorders belong to the prodrome of bipolar disorder? A clinical study combining retrospective and prospective methods to analyse the relationship between anxiety disorder and bipolar disorder from the perspective of biorhythms" 17 : 351-, 2017

70 Agren T, "Disruption of reconsolidation erases a fear memory trace in the human amygdala" 337 : 1550-1552, 2012

71 Björkstrand J, "Disruption of memory reconsolidation erases a fear memory trace in the human amygdala: an 18-month follow-up" 10 : e0129393-, 2015

72 Lepow L, "Critical period plasticity as a framework for psychedelic-assisted psychotherapy" 15 : 710004-, 2021

73 Pomara N, "Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder" 178 : 1-8, 2004

74 Foa EB, "Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?" 52 : 987-997, 2002

75 Spoorthy MS, "Comorbidity of bipolar and anxiety disorders: an overview of trends in research" 9 : 7-29, 2019

76 Mitchell JD, "Comorbid disorders in patients with bipolar disorder and concomitant substance dependence" 102 : 281-287, 2007

77 MacKinnon DF, "Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder" 159 : 30-35, 2002

78 Otto MW, "Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes" 17 : 91-103, 2010

79 Coupland NJ, "Combined antidepressants and CBT for panic disorder with agoraphobia" 33 : 176-, 2008

80 Barlow DH, "Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial" 283 : 2529-2536, 2000

81 Barlow DH, "Cognitive-behavioral therapy for panic disorder: current status" 58 (58): 32-36, 1997

82 Hofmann SG, "Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials" 69 : 621-632, 2008

83 Yoshinaga N, "Cognitive behavioral therapy for patients with social anxiety disorder who remain symptomatic following antidepressant treatment: a randomized, assessor-blinded, controlled trial" 85 : 208-217, 2016

84 Frank E, "Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder" 59 : 905-911, 2002

85 Shin J, "Clinical implications of agoraphobia in patients with panic disorder" 99 : e21414-, 2020

86 Katzman MA, "Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders" 14 (14): S1-, 2014

87 Doughty CJ, "Bipolar-panic disorder comorbidity within bipolar disorder families: a study of siblings" 6 : 245-252, 2004

88 Simon NM, "Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD)" 161 : 2222-2229, 2004

89 Coryell W, "Anxiety and outcome in bipolar disorder" 166 : 1238-1243, 2009

90 Gitlin MJ, "Antidepressants in bipolar depression: an enduring controversy" 6 : 25-, 2018

91 Wetherell JL, "Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults" 170 : 782-789, 2013

92 Tremolizzo L, "An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability" 99 : 17095-17100, 2002

93 Marks IM, "Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto" 162 : 776-787, 1993

94 Perugi G, "Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year “open” follow-up study" 260 : 553-560, 2010

95 Womer FY, "A ventral prefrontalamygdala neural system in bipolar disorder: a view from neuroimaging research" 21 : 228-238, 2009

96 Rao-Ruiz P, "A synaptic framework for the persistence of memory engrams" 13 : 661476-, 2021

97 Nader K, "A single standard for memory: the case for reconsolidation" 10 : 224-234, 2009

98 Shiroma PR, "A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression" 10 : 206-, 2020